Vicore further strengthens patent protection for C21

Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”) today announces that the European Patent Office (EPO) has granted Vicore’s patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF).

The European patent protection:

• relates to any form of enteric coating of C21, and

• is not limited to any specific disease

Read more…